© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#abacavir

What’s the Skinny on Bone Health for People With HIV?

Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.

Switching Off Ziagen Is Linked to Healthier Platelets in People With HIV

Ziagen is included in the combination-tablet regimens Triumeq and Trizivir and the two-drug combo tablet Epzicom.

Switching to Two-Drug HIV Regimen Would Save Big Money

The regimen of Tivicay (dolutegravir) and Epivir (lamivudine) would be a highly cost-effective first-line option and save a great deal.

High Marks for Merck’s Hep C Treatment in Those With HIV

Merck’s investigational hepatitis C treatment grazoprevir/elbasvir cured high rates of the virus among individuals coinfected with HIV.

HIV Essentially Doubles Aging’s Effect on Heart Attack Risk

Every decade spent living with HIV is equivalent to an additional 10 years of ordinary aging’s contribution to heart attack risk.

Certain HIV Meds Raise Risk of Heart Trouble

Various HIV antiretrovirals are linked to a raised risk of cardiovascular problems, although the overall risk of such an outcome is still low.

Individual HIV Meds Are Just as Effective as Combo Pills

Multi-antiretroviral combination tablets appear to combat HIV no better than regimens that include individual tablets.

HIV Treatment Guidelines Nix Atripla as First-Line Therapy

A revision of U.S. HIV treatment guidelines has removed Atripla (efavirenz/tenofovir/emtricitabine) from the priority list of first-line antir...

People With HIV and Kidney Problems Should Avoid Viread (Tenofovir)

While antiretroviral therapy is beneficial for HIV-positive people with reduced kidney function, they should not take Viread (tenofovir).

Tenofovir Tied to Kidney Damage in Those With Low Body Weight

There is an apparent link between taking Viread (tenofovir) and developing kidney damage among HIV-positive people with low body weight.

FDA Approves New Single-Tablet HIV Regimen, Triumeq

The FDA has approved Triumeq, ViiV Healthcare’s single-tablet, triple-combination antiretroviral regimen, as a first-line therapy to treat..

Many People With HIV Could Switch to Newer, Safer Regimens

A majority of people taking antiretrovirals to treat HIV could switch to newer regimens with improved side effect profiles.

Merck’s Hep C Drugs Show Promise for HIV Coinfection

Early results of Merck’s combination hepatitis C therapy showed comparable safety between those with or without HIV, plus near-perfect cure ra...

ViiV Submits Single-Pill Combo of Tivicay and Epzicom to FDA

ViiV Healthcare has submitted an application to the FDA for approval of a single-tablet regimen to treat HIV that combines Tivicay and Epzicom...

Kaletra and Epivir Dual Therapy Works as Well as Triple Combo

Treating HIV with a dual regimen of Kaletra and Epivir is as effective as a standard triple regimen of Kaletra plus two NRTIs.

Government Shutdown May Slow FDA Drug Approvals

The looming threat of a government shutdown on October 1 may spell potential delays in Food and Drug Administration approvals of new drugs.
Advertisement